UnitedHealth Group Incorporated’s UNH Optum Rx delivered higher operating earnings despite declining prescription volumes in the third quarter of 2026. Stronger profitability, supported by biosimilar adoption and operational efficiencies, highlights the segment's resilience amid membership-related pressures. However, sustaining this momentum without a recovery in prescription activity remains a key challenge.
Optum Rx revenues edged up to $39.9 billion from $39.7 billion a year earlier. Operating earnings increased 10.9% to $1.72 billion, expanding the operating margin to 4.3% from 3.9%. Adjusted prescriptions declined 5.1% to 393 million, reflecting membership losses at UnitedHealthcare and other customers. The contrasting trends suggest that improving operating performance is helping offset weaker prescription activity.
Specialty pharmacy offers an additional growth opportunity. Management reported a 2.6% increase in specialty volumes during the quarter, supported by strong demand for complex therapies and expanding provider relationships. Optum Rx is also strengthening its integrated pharmacy services, including infusion offerings, while advancing transparent pharmacy benefit pricing. These initiatives could support customer retention, improve business mix and provide additional earnings opportunities.
Nevertheless, continued membership attrition could restrict overall prescription growth, while evolving pharmacy pricing arrangements may influence future profitability. Sustained margin expansion will require disciplined cost management and successful execution of higher-value pharmacy services. Although the segment has demonstrated its ability to improve profitability amid softer volumes, a recovery in prescription activity would provide a more durable foundation for earnings growth through 2027.
How Are UNH's Peers Positioned?
UnitedHealth's Medical sector peers, The Cigna Group CI and CVS Health Corporation CVS, also illustrate how business mix and operating discipline affect profitability.
Cigna's Evernorth reported 6% growth in adjusted revenues in the third quarter of 2026, but adjusted pretax operating earnings declined 4%. Cigna’s Pharmacy Benefit Services earnings fell 22%, while Specialty and Care Services earnings rose 15%, partly reflecting biosimilar and specialty generic adoption.
CVS's Health Services segment reported 9.5% revenue growth and a 2.7% increase in adjusted operating income during the quarter. Pharmacy claims processed increased 1.3% on a 30-day equivalent basis. Unlike Optum Rx, CVS reported volume growth, underscoring different operating dynamics across the industry.
UNH’sPrice Performance, Valuation & Estimates
Shares of UnitedHealth have risen 22.8% year to date compared with the industry’s 25.7% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, UNH trades at a forward price-to-earnings ratio of 17.6 compared with the industry average of 15.68. UNH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UnitedHealth’s 2026 earnings is pegged at $20.61 per share, implying a 20.06% increase from the year-ago period’s level.
Image Source: Zacks Investment Research
UNH currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Cigna Group (CI): Free Stock Analysis Report
CVS Health Corporation (CVS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).